Melissa Palmer

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 6

Top Topics

Pulmonary Embolism

Top Venues

Alimentary pharmacology & therapeutics

BMC pharmacology & toxicology

This page only lists publications with an associated author ORCID identifier.

Publications

Anna Fettiplace, John Marcinak, Michael Merz, Hui-Talia Zhang, Luciana Kikuchi, Arie Regev, Melissa Palmer, Don C Rockey, Robert Fontana, Paul H Hayashi, Hans L Tillmann, Adrian M Di Bisceglie, James H Lewis
Review article: Recommendations for detection, assessment and management of suspected drug-induced liver injury during clinical trials in oncology patients. Alimentary pharmacology & therapeutics (2024)
Melissa Palmer, David E Kleiner, Zachary Goodman, Elizabeth Brunt, Mark I Avigan, Arie Regev, Paul H Hayashi, James H Lewis, Ruby Mehta, Stephen A Harrison, Massimo Siciliano, Charles A McWherter, Raj K Vuppalanchi, Cynthia Behling, Veronica Miller, Naga P Chalasani, Arun J Sanyal
Liver biopsy for assessment of suspected drug-induced liver injury in metabolic dysfunction-associated steatohepatitis clinical trials: Expert consensus from the Liver Forum. Alimentary pharmacology & therapeutics (2023)
Arie Regev, Melissa Palmer, Mark I Avigan, Lara Dimick-Santos, William R Treem, John F Marcinak, Daniel Seekins, Gopal Krishna, Frank A Anania, James W Freston, James H Lewis, Arun J Sanyal, Naga Chalasani
Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis. Alimentary pharmacology & therapeutics 49 (6) (2019)
Kanita Salic, Robert Kleemann, Cynthia Wilkins-Port, John McNulty, Lars Verschuren, Melissa Palmer
Apical sodium-dependent bile acid transporter inhibition with volixibat improves metabolic aspects and components of non-alcoholic steatohepatitis in Ldlr-/-.Leiden mice. PloS one 14 (6) (2019)
Melissa Palmer, Arie Regev, Keith Lindor, Mark I Avigan, Lara Dimick-Santos, William Treem, John F Marcinak, James H Lewis, Frank A Anania, Daniel Seekins, Benjamin L Shneider, Naga Chalasani
Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease. Alimentary pharmacology & therapeutics 51 (1) (2019)
Melissa Palmer, Lee Jennings, Debra G Silberg, Caleb Bliss, Patrick Martin
A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis. BMC pharmacology & toxicology 19 (1) (2018)